Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents

Joe Sasadeusz, Andrew Grigg, Peter D. Hughes, Seng Lee Lim, Michaela Lucas, Geoff McColl, Sue Anne McLachlan, Marion G. Peters, Nicholas Shackel, Monica Slavin, Vijaya Sundararajan, Alexander Thompson, Joseph Doyle, James Rickard, Peter De Cruz, Robert G. Gish, Kumar Visvanathan

Research output: Contribution to journalReview ArticleOtherpeer-review


Because of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided.

Original languageEnglish
Pages (from-to)521-534
Number of pages14
JournalClinics in Liver Disease
Issue number3
Publication statusPublished - 1 Aug 2019


  • Anti-CD20
  • Direct-acting antivirals
  • Hepatitis B
  • Inflammatory bowel diseases
  • Reactivation
  • Rheumatoid arthritis

Cite this